FMP

FMP

Enter

IDXG - Interpace Bioscience...

photo-url-https://images.financialmodelingprep.com/symbol/IDXG.png

Interpace Biosciences, Inc.

IDXG

PNK

Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; PanDNA, a molecular only version of PancraGEN that provides physicians a snapshot of a limited number of factors; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.

0.89 USD

-0.03 (-3.37%)

Operating Data

Year

2020

2021

2022

2023

2024

2025

2026

2027

2028

2029

Revenue

132.51M

170.36M

310.02M

363.14M

414.29M

561.12M

760M

1.03B

1.39B

1.89B

Revenue %

-

28.57

81.98

17.13

14.09

35.44

35.44

35.44

35.44

Ebitda

-39.8M

-38.71M

-130.92M

-110.34M

-71.19M

-159.98M

-216.68M

-293.48M

-397.5M

-538.38M

Ebitda %

-30.03

-22.72

-42.23

-30.39

-17.18

-28.51

-28.51

-28.51

-28.51

Ebit

-48.31M

-46.92M

-173.53M

-157.72M

-116.36M

-214.91M

-291.07M

-394.23M

-533.96M

-723.2M

Ebit %

-36.46

-27.54

-55.97

-43.43

-28.09

-38.3

-38.3

-38.3

-38.3

Depreciation

8.52M

8.21M

42.61M

47.38M

45.16M

54.92M

74.39M

100.75M

136.46M

184.82M

Depreciation %

6.43

4.82

13.74

13.05

10.9

9.79

9.79

9.79

9.79

Balance Sheet

Year

2020

2021

2022

2023

2024

2025

2026

2027

2028

2029

Total Cash

84.32M

433.88M

365.85M

321.08M

237.03M

459.3M

622.08M

842.56M

1.14B

1.55B

Total Cash %

63.64

254.69

118.01

88.42

57.21

81.85

81.85

81.85

81.85

Receivables

1.19M

11.84M

30.8M

26.7M

27.7M

35.71M

48.36M

65.5M

88.72M

120.17M

Receivables %

0.9

6.95

9.94

7.35

6.69

6.36

6.36

6.36

6.36

Inventories

1.65M

2.3M

3.02M

4.02M

-15.81M

964.26k

1.31M

1.77M

2.4M

3.24M

Inventories %

1.24

1.35

0.97

1.11

-3.82

0.17

0.17

0.17

0.17

Payable

5.27M

7.39M

7.84M

10.15M

13.75M

19.03M

25.78M

34.92M

47.29M

64.05M

Payable %

3.98

4.34

2.53

2.8

3.32

3.39

3.39

3.39

3.39

Cap Ex

-3.31M

-2.37M

-3.62M

-7.23M

-12.48M

-11.29M

-15.29M

-20.71M

-28.05M

-37.99M

Cap Ex %

-2.5

-1.39

-1.17

-1.99

-3.01

-2.01

-2.01

-2.01

-2.01

Weighted Average Cost Of Capital

Price

6.89

Beta

Diluted Shares Outstanding

74.91M

Costof Debt

4.43

Tax Rate

After Tax Cost Of Debt

4.43

Risk Free Rate

Market Risk Premium

Cost Of Equity

Total Debt

241.65M

Total Equity

516.11M

Total Capital

757.76M

Debt Weighting

31.89

Equity Weighting

68.11

Wacc

10.9

Build Up Free Cash Flow

Year

2020

2021

2022

2023

2024

2025

2026

2027

2028

2029

Revenue

132.51M

170.36M

310.02M

363.14M

414.29M

561.12M

760M

1.03B

1.39B

1.89B

Ebitda

-39.8M

-38.71M

-130.92M

-110.34M

-71.19M

-159.98M

-216.68M

-293.48M

-397.5M

-538.38M

Ebit

-48.31M

-46.92M

-173.53M

-157.72M

-116.36M

-214.91M

-291.07M

-394.23M

-533.96M

-723.2M

Tax Rate

-1.25

-1.25

-1.25

-1.25

-1.25

-1.25

-1.25

-1.25

-1.25

-1.25

Ebiat

-48.43M

-46.93M

-165.93M

-156.49M

-117.81M

-212.69M

-288.07M

-390.16M

-528.45M

-715.74M

Depreciation

8.52M

8.21M

42.61M

47.38M

45.16M

54.92M

74.39M

100.75M

136.46M

184.82M

Receivables

1.19M

11.84M

30.8M

26.7M

27.7M

35.71M

48.36M

65.5M

88.72M

120.17M

Inventories

1.65M

2.3M

3.02M

4.02M

-15.81M

964.26k

1.31M

1.77M

2.4M

3.24M

Payable

5.27M

7.39M

7.84M

10.15M

13.75M

19.03M

25.78M

34.92M

47.29M

64.05M

Cap Ex

-3.31M

-2.37M

-3.62M

-7.23M

-12.48M

-11.29M

-15.29M

-20.71M

-28.05M

-37.99M

Ufcf

-40.79M

-50.27M

-146.17M

-110.92M

-62.72M

-188.55M

-235.22M

-318.59M

-431.5M

-584.44M

Wacc

10.9

10.9

10.9

10.9

10.9

Pv Ufcf

-170.02M

-191.26M

-233.58M

-285.27M

-348.4M

Sum Pv Ufcf

-1.23B

Terminal Value

Growth In Perpetuity Method

Long Term Growth Rate

Wacc

10.9

Free Cash Flow T1

-596.13M

Terminal Value

-6.7B

Present Terminal Value

-4B

Intrinsic Value

Enterprise Value

-5.22B

Net Debt

55.93M

Equity Value

-5.28B

Diluted Shares Outstanding

74.91M

Equity Value Per Share

-70.48

Projected DCF

-70.48 1.098%

DCF Levered

Download Excel

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep